Company Overview and News
MBM Resources Bhd (Oct 8, RM2.06) Recommend buy with a target price (TP) of RM3.40: MBM Resources Bhd’s growth remains intact with a higher sales volume expected from Perodua and a potential turnaround of its alloy wheel business. We recommend “buy” with a TP of RM3.40 based on 11 times its financial year 2019 (FY19) price-earnings ratio (PER) premised on its five-year average PER.
KUALA LUMPUR (Sept 14): The FBM KLCI rose 0.61% and crossed the 1,800 level at midday break, in line with gains at regional markets, as sentiment received a boost from expectations of fresh US-China negotations.
7084 BATS 4162 5983 0096 7123 5199 CIMDF 1023 3026 1201 3867 6645 4405 HIPEF
KUALA LUMPUR: Shares in DRB-Hicom Bhd rose as much as 9.3% yesterday, as investors reacted positively to news regarding a joint venture (JV) between its 50.1%-owned subsidiary Proton Holdings Bhd and China’s Zhejiang Geely Holding Group that will pave the way for Proton to assemble and market its cars in China.
4588 SMEBF 4405 4197 5983 BSMAF 1818
KUALA LUMPUR: More voices have weighed in on Prime Minister Tun Dr Mahathir Mohamad’s plan to restrict the import of foreign cars and start a third national car, and the tone was mostly negative.
4588 SMEBF 4405 4197 5015 5983 BSMAF 3034 1818
KUALA LUMPUR (July 31): The government's reported move of looking at setting limits on foreign car imports had a mild impact on counters linked to the automotive industry this morning.
4588 SMEBF 4405 4197 5015 5983 3034
MBM Resources Bhd (July 10, RM2.40) Maintain buy with an unchanged target price of RM3.19: To recap, Hino Motors established its first assembly plant in Malaysia, with 58% holdings, whilse MBM Resources Bhd holds a 42% stake. The plant was completed in 2014 in Sendayan, Negeri Sembilan and has a capacity of 10,000 units per annum.
HINOF HINOY 7205 5983
KUALA LUMPUR (July 10): The High Court has ruled that the appointment of two directors to the board of Med-Bumikar Mara Sdn Bhd was invalid following an eight-hour hearing today.
KUALA LUMPUR (June 29): Based on corporate announcements and news flow today, stocks in focus for Monday (July 2) may include the following: Malaysia Airports Holdings Bhd, Sapura Energy Bhd, MBM Resources Bhd, Parkson Holdings Bhd and Green Packet Bhd.
O9E SPXCF PMOIF 0082 PMO 5983 5014 S68 5657 SPXCY MYPRY BSMAF PMOIY 1818
KUALA LUMPUR (June 29): Automotive parts maker MBM Resources Bhd has appointed its 51.5%-owned subsidiary Daihatsu (Malaysia) Sdn Bhd’s managing director Dr Muhammad Iqbal Shaharom as the group's president and chief executive officer.
5983 BSMAF 1818
IN a month, the shareholder tussle at Med-Bumikar Mara Sdn Bhd over its majority stake in MBM Resources Bhd (MBMR) is set to resume following the last court hearing in May. But “vehement” objections by a key Japanese partner remain a stumbling block for UMW Holdings Bhd, even if the conglomerate manages to take control of MBMR.
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...